Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
FiercePharma3d
JPM25: Bayer gears up for 'must-win battles' as Xarelto's decline is in full swing, pharma chief says
These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Bayer to Scale Back Health Dealmaking Amid Push to Pay Down Debt
Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...
Bayer sees new drugs boosting return to growth in 2027, WSJ reports
Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...
pharmaphorum20h
Bayer applies artificial intelligence to its pharmacovigilance systems
Bayer is looking to accelerate its patient ... related side effects to be detected much earlier. The German pharmaceutical company has tied up with professional services firm Genpact for the ...
FierceBiotech5d
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more
It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...
devdiscourse4d
Health Industry Challenges and Developments: A Comprehensive Update
This health news update covers Bayer's $100 million payout over PCBs, Biogen's future strategy, Pfizer's appeal in an SEC ...
Reuters3d
Bayer AG
including boosting efficiency and drug development, to restore confidence and revive the company's share price that hit 20-year lows after its shock warning this week. Bayer shareholders call on ...